Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
Crossref DOI link: https://doi.org/10.1007/s12325-021-01675-0
Published Online: 2021-04-21
Published Print: 2021-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Melillo, Giovanni
Chand, Vikram
Yovine, Alejandro
Gupta, Ashok
Massacesi, Cristian
Funding for this research was provided by:
AstraZeneca
Text and Data Mining valid from 2021-04-21
Version of Record valid from 2021-04-21
Article History
Received: 22 January 2021
Accepted: 16 February 2021
First Online: 21 April 2021